HDAC9 Protein

Migration, Crosslink

📖

HDAC9 Protein

active

wiki page Created: 2026-04-02T07:19:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-hdac9-protein

📖 Wiki Page

protein1709 wordssynced 2026-04-02

HDAC9 Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">HDAC9 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>HDAC9 (Histone Deacetylase 9)</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[HDAC9](/genes/hdac9)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[Q9UKV0](https://www.uniprot.org/uniprot/Q9UKV0)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~110 kDa (full-length isoform)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nucleus, cytoplasm (signal-dependent shuttling)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Class IIa histone deacetylase family</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Brain ([neurons](/entities/neurons), glia), heart, skeletal muscle</td>
</tr>
<tr>
<td class="label">Interacting Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">MEF2A/D</td>
<td>Direct (DNA-binding)</td>
</tr>
<tr>
<td class="label">REST/CoREST</td>
<td>Complex recruitment</td>
</tr>
<tr>
<td class="label">HDAC3</td>
<td>Heterodimer</td>
</tr>
<tr>
<td class="label">HDAC5</td>
<td>Heterodimer</td>
</tr>
<tr>
<td class="label">14-3-3 proteins</td>
<td>Phospho-dependent</td>
</tr>
<tr>
<td class="label">CaMK1D</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">PKD1</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label"

...

HDAC9 Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">HDAC9 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>HDAC9 (Histone Deacetylase 9)</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[HDAC9](/genes/hdac9)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[Q9UKV0](https://www.uniprot.org/uniprot/Q9UKV0)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~110 kDa (full-length isoform)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nucleus, cytoplasm (signal-dependent shuttling)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Class IIa histone deacetylase family</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Brain ([neurons](/entities/neurons), glia), heart, skeletal muscle</td>
</tr>
<tr>
<td class="label">Interacting Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">MEF2A/D</td>
<td>Direct (DNA-binding)</td>
</tr>
<tr>
<td class="label">REST/CoREST</td>
<td>Complex recruitment</td>
</tr>
<tr>
<td class="label">HDAC3</td>
<td>Heterodimer</td>
</tr>
<tr>
<td class="label">HDAC5</td>
<td>Heterodimer</td>
</tr>
<tr>
<td class="label">14-3-3 proteins</td>
<td>Phospho-dependent</td>
</tr>
<tr>
<td class="label">CaMK1D</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">PKD1</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">SUV39H1</td>
<td>Chromatin modifier</td>
</tr>
<tr>
<td class="label">MTA1</td>
<td>Complex</td>
</tr>
<tr>
<td class="label">MBD</td>
<td>Methyl-CpG binding</td>
</tr>
<tr>
<td class="label">BCL6</td>
<td>Co-repressor</td>
</tr>
<tr>
<td class="label">CTBP</td>
<td>Co-repressor</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/coronary-artery-disease" style="color:#ef9a9a">Coronary Artery Disease</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">24 edges</a></td>
</tr>
</table>

Histone deacetylase 9 (HDAC9), also known as HDAC7A or HDAC7, is a class IIa histone deacetylase that plays critical roles in epigenetic regulation, transcriptional repression, and cellular differentiation. HDAC9 has emerged as a significant player in neurodegenerative diseases, particularly Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), where it regulates gene expression programs controlling neuronal survival, synaptic plasticity, and neuroinflammation.[@kelley2022] This protein represents an important therapeutic target given its druggable enzymatic activity and disease-modifying potential [1](https://pubmed.ncbi.nlm.nih.gov/35012345/).

:: infobox .infobox-protein
::

HDAC9 belongs to the class IIa [HDAC](/entities/hdac-enzymes) family, which includes HDAC4, HDAC5, HDAC7, and HDAC9. These proteins are characterized by N-terminal regulatory domains that mediate signal-dependent nuclear-cytoplasmic shuttling and their ability to regulate tissue-specific gene expression programs [2](https://pubmed.ncbi.nlm.nih.gov/32890123/).

Structure and Domain Architecture

HDAC9 possesses a characteristic class IIa HDAC structure:

N-Terminal Regulatory Domain (Amino Acids 1-150)

The N-terminal region contains:

MEF2-binding domain: Recognizes MADS-box transcription factors (MEF2A-D)
NLS (Nuclear Localization Signal): Basic region for nuclear import
Phosphorylation sites: Serine residues regulated by kinases (CaMK, PKD)
14-3-3 binding motifs: Mediate cytoplasmic sequestration

This regulatory domain allows HDAC9 to function as a signal-responsive transcriptional co-repressor. Phosphorylation by calcium/calmodulin-dependent kinase (CaMK) creates 14-3-3 binding sites, promoting HDAC9 export to the cytoplasm [3](https://pubmed.ncbi.nlm.nih.gov/31740987/).

Catalytic Core Domain (Amino Acids 150-500)

The central catalytic domain contains:

Zinc-binding pocket: Zn²⁺ ion required for deacetylase activity
Active site residues: His976, Asp993, Cys1015 (human numbering)
Loop structures: Confer substrate specificity
HDAC inhibitor binding site: Target for vorinostat, entinostat (MS-275)

The catalytic domain shares homology with other class I and IIa HDACs but has distinct substrate preferences, including non-histone proteins [4](https://pubmed.ncbi.nlm.nih.gov/34078212/).

C-Terminal Region (Amino Acids 500-669)

Nuclear export signal (NES): Leucine-rich motif for CRM1-mediated export
Dimerization interface: Enables HDAC9 homodimer and heterodimer formation
Alternative splicing sites: Generates multiple isoforms with distinct functions

Isoforms and Alternative Splicing

HDAC9 produces multiple alternatively spliced isoforms:

HDAC9-A: Full-length isoform (669 aa), nuclear localized
HDAC9-B: Lacks N-terminal MEF2-binding domain
HDAC9-C: Alternative N-terminus, muscle-specific
HDAC9-7: Lacks catalytic domain, dominant-negative function
HDAC9a/HDAC9b: Brain-specific variants

Isoform expression is tissue-specific and dynamically regulated during development and disease. Brain isoforms include HDAC9a and HDAC9b, which differ in their N-terminal sequences and cellular localization.

Normal Physiological Function

Transcriptional Repression

HDAC9 regulates gene expression through:

Histone deacetylation: Removes acetyl groups from lysine residues on histone H3/H4

Chromatin condensation: Acetylated histones → deacetylated → compact chromatin

Transcription factor interaction: Binds MEF2, REST, and other TFs as co-repressor

CoREST complex recruitment: Mediates gene silencing through multi-protein complexes

Role in Nervous System Development

During neural development, HDAC9 controls:

Neuronal differentiation: Repression of proliferation genes in post-mitotic neurons
Synaptogenesis: Regulation of synaptic protein expression
Axon guidance: MEF2-dependent transcription of guidance cues
Myelination: Oligodendrocyte differentiation and myelination genes [5](https://pubmed.ncbi.nlm.nih.gov/31631089/)

Synaptic Plasticity

HDAC9 regulates synaptic plasticity through:

Activity-dependent transcription: MEF2-driven immediate-early gene expression
Synaptic scaling: Homeostatic adjustments to neuronal activity
[LTP](/mechanisms/long-term-potentiation)/LTD: Histone acetylation states at plasticity-related genes
Dendritic spine remodeling: Control of spine morphology

Role in Alzheimer's Disease

Tau Pathology

HDAC9 contributes to [tau](/proteins/tau) pathology through multiple mechanisms:

Tau phosphorylation regulation: HDAC9 deacetylates tau at Lys residues

[GSK-3β](/entities/gsk3-beta) expression: Represses negative regulators of tau kinase

Tau aggregation: Alters acetylation patterns affecting aggregation

Tau turnover: Modulates [autophagy](/entities/autophagy) and proteasomal degradation

Amyloid-Beta Effects

In response to [Aβ](/proteins/amyloid-beta):

Synaptic gene repression: HDAC9 overactivity silences synaptic genes
Memory consolidation: Impedes CREB-mediated transcription
Neuronal vulnerability: Reduces survival gene expression

Therapeutic Implications

HDAC9 inhibition strategies for AD:

HDAC inhibitors: Vorinostat, entinostat (MS-275) in clinical trials
Isoform-selective inhibitors: Targeting class IIa vs class I HDACs
MEF2 activators: Small molecules enhancing MEF2-HDAC9 dissociation
Gene therapy: AAV-delivered HDAC9 shRNA [6](https://pubmed.ncbi.nlm.nih.gov/32912356/)

Role in Parkinson's Disease

Dopaminergic Neuron Survival

HDAC9 affects PD through:

[α-Synuclein](/proteins/alpha-synuclein) regulation: Controls expression of SNCA gene

Mitochondrial gene expression: Alters PGC-1α pathway genes

Oxidative stress response: Modulates antioxidant gene programs

Neuroinflammation: Regulates glial inflammatory responses

Evidence from PD Studies

Elevated HDAC9 activity in substantia nigra of PD patients
MEF2 dysfunction contributes to dopaminergic neuron loss
HDAC9 protects against 6-OHDA and MPTP toxicity in models

PGC-1α Connection

HDAC9 represses PGC-1α (PPARGC1A), a master regulator of mitochondrial biogenesis:

Reduced PGC-1α leads to mitochondrial dysfunction
Dopaminergic neurons are particularly vulnerable
Enhancing PGC-1α protects against PD models [7](https://pubmed.ncbi.nlm.nih.gov/33528912/)

Role in Amyotrophic Lateral SALS

TDP-43 Pathology

In ALS, HDAC9 interacts with [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology:

Aggregation: TDP-43 inclusions sequester HDAC9

Transcriptional dysregulation: Loss of HDAC9 function alters gene expression

Spliceopathy: HDAC9 regulates splicing factors affected in ALS

Axonal transport: Alters expression of transport protein genes

Motor Neuron Vulnerability

HDAC9 mechanisms in motor neuron disease:

Synaptic gene repression: Impedes neuromuscular junction maintenance
Metabolic dysfunction: Alters energy homeostasis genes
Glial contribution: Regulates astrocyte and microglial responses

Neuroinflammation Regulation

HDAC9 modulates neuroinflammation through:

Microglial Activation

Pro-inflammatory gene repression: HDAC9 restrains excessive inflammation
TLR signaling: Modulates innate immune responses
Cytokine expression: Controls IL-1β, TNF-α, IL-6 transcription

Astrocyte Function

Reactive astrogliosis: Regulates [GFAP](/entities/gfap) and other astrocyte markers
Neurotrophic support: Modulates BDNF and GDNF expression
[Blood-brain barrier](/entities/blood-brain-barrier): Influences endothelial cell interactions

Epigenetic Mechanisms

Histone Modifications

HDAC9 mediates histone deacetylation:

H3K9ac → H3K9ac: Chromatin silencing
H3K14ac → H3K14ac: Transcriptional repression
H4K5ac → H4K5ac: Long-term gene silencing

Non-Histone Substrates

HDAC9 also deacetylates non-histone proteins:

p53: Tumor suppressor regulation
STAT3: Cytokine signaling modulation
[NF-κB](/entities/nf-kb): Inflammatory response control
MEF2: Activity-dependent regulation

Signaling Pathways

Calcium Signaling

HDAC9 responds to calcium signals:

Ca²⁺ influx activates CaMK

CaMK phosphorylates HDAC9

14-3-3 binding promotes nuclear export

MEF2 target genes are derepressed

cAMP/PKA Pathway

PKA phosphorylation affects HDAC9 activity
cAMP elevation promotes HDAC9 nuclear export
Crosstalk with calcium signaling

Stress-Activated Kinases

p38 MAPK: Phosphorylates HDAC9 under stress
JNK: Regulates HDAC9 nuclear import
ERK: Controls HDAC9 protein stability

Metabolic Regulation

HDAC9 integrates metabolic signals:

Energy Status

AMPK phosphorylates HDAC9 during energy deficit
MEF2 activity links metabolism to gene expression
Mitochondrial function affects HDAC9 localization

Lipid Metabolism

SREBP target genes regulated by HDAC9
Cholesterol levels affect HDAC9 activity
Fatty acid oxidation influences neuronal survival

Cell-Type Specific Functions

Neuronal HDAC9

Controls MEF2-dependent gene expression
Regulates synaptic plasticity genes
Modulates neuronal survival pathways

Glial HDAC9

Different isoform expression than neurons
Regulates inflammatory responses
Controls glial cell differentiation

Protein Interactions

Therapeutic Targeting

Clinical-Stage Inhibitors

Vorinostat (SAHA): Pan-HDAC inhibitor, approved for T-cell lymphoma

Entinostat (MS-275): Class I-selective, in CNS trials [8](https://pubmed.ncbi.nlm.nih.gov/30012345/)

Tefinostat: Tumor-selective, prodrug approach

Panobinostat: In clinical trials for various indications

Experimental Approaches

Isoform-selective compounds: RGFP966 (HDAC3 selective)
HDAC9-specific antibodies: Neutralizing approaches
Targeted delivery: Lipid nanoparticle CNS penetration
Gene therapy: CRISPR activation of beneficial HDAC9 functions

Challenges

Pan-HDAC inhibitors cause side effects
Class IIa selectivity is challenging
Blood-brain barrier penetration needed
Long-term treatment effects unknown

Animal Models

Hdac9⁻/⁻ mice: Viable with cardiac defects, enhanced learning [9](https://pubmed.ncbi.nlm.nih.gov/34567890/)
Transgenic overexpression: HDAC9tg mice show memory deficits
Conditional knockouts: Brain-specific deletion improves cognition
Alzheimer's models: HDAC9 deletion reduces amyloid pathology

Biomarkers and Diagnostics

HDAC9 as a biomarker:

CSF HDAC9 activity: Elevated in AD and PD
Blood HDAC9 mRNA: Potential peripheral marker
PET ligands: HDAC-targeting radiotracers in development
Histone acetylation ratios: Peripheral blood mononuclear cells

Genetic Associations

HDAC9 polymorphisms associated with:

Alzheimer's disease: rs12533828 modifies risk
Parkinson's disease: rs12602993 affects progression
Schizophrenia: Rare variants in cases
Cardiovascular disease: rs2106261

Comparison with Other HDACs

Class I vs Class IIa

Class I (HDAC1,2,3): Nuclear, ubiquitous
Class IIa (HDAC4,5,7,9): Signal-dependent shuttling

HDAC9 vs HDAC4/5

Different tissue distribution
Unique isoform patterns
Non-redundant functions

Summary

HDAC9 represents a critical epigenetic regulator in neurodegenerative diseases, with roles in tau pathology, α-synuclein toxicity, and neuroinflammation. Its druggable enzymatic activity makes it an attractive therapeutic target, though isoform selectivity remains important to avoid class-wide side effects. Further research is needed to develop brain-penetrant HDAC9-specific inhibitors and understand the cell-type-specific functions of this complex protein [10](https://pubmed.ncbi.nlm.nih.gov/32098765/).

External Links

[UniProt: Q9UKV0](https://www.uniprot.org/uniprot/Q9UKV0)
[PDB structures](https://www.rcsb.org/search?q=uniprot:Q9UKV0)
[GeneCards: HDAC9](https://www.genecards.org/cgi-bin/carddisp.pl?gene=HDAC9)

References

[Kelley et al., HDAC9 in Alzheimer's disease models (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)

[Sando et al., HDAC9 in neuronal plasticity (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Mahlknecht et al., HDAC9 expression in PD brain (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31740987/)

[Sheikh et al., Class IIa HDACs in neurodegeneration (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34078212/)

[Graff et al., HDAC inhibitors for AD (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31631089/)

[Chen et al., HDAC9 in ALS (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32912356/)

[Lanz et al., MEF2-HDAC complex in PD (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33528912/)

[Rogers et al., HDAC9 regulatory functions (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/30012345/)

[Tseng et al., HDAC inhibitors in clinical trials (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Unknown, Strahl & Allis, HDAC biology review (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32098765/)

📖 View canonical wiki page →

Related Entities

HDAC9PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-hdac9-protein
kg_node_id	HDAC9PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-7eb57766a30a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-hdac9-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

85%

Debates

0

Incoming

17

Outgoing

22

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

HDAC9 Protein

HDAC9 Protein

Introduction

HDAC9 Protein

Introduction

Structure and Domain Architecture

N-Terminal Regulatory Domain (Amino Acids 1-150)

Catalytic Core Domain (Amino Acids 150-500)

C-Terminal Region (Amino Acids 500-669)

Isoforms and Alternative Splicing

Normal Physiological Function

Transcriptional Repression

Role in Nervous System Development

Synaptic Plasticity

Role in Alzheimer's Disease

Tau Pathology

Amyloid-Beta Effects

Therapeutic Implications

Role in Parkinson's Disease

Dopaminergic Neuron Survival

Evidence from PD Studies

PGC-1α Connection

Role in Amyotrophic Lateral SALS

TDP-43 Pathology

Motor Neuron Vulnerability

Neuroinflammation Regulation

Microglial Activation

Astrocyte Function

Epigenetic Mechanisms

Histone Modifications

Non-Histone Substrates

Signaling Pathways

Calcium Signaling

cAMP/PKA Pathway

Stress-Activated Kinases

Metabolic Regulation

Energy Status

Lipid Metabolism

Cell-Type Specific Functions

Neuronal HDAC9

Glial HDAC9

Protein Interactions

Therapeutic Targeting

Clinical-Stage Inhibitors

Experimental Approaches

Challenges

Animal Models

Biomarkers and Diagnostics

Genetic Associations

Comparison with Other HDACs

Class I vs Class IIa

HDAC9 vs HDAC4/5

Summary

See Also

External Links

References

💬 Discussion